on behalf of the Catalan Stroke Code and Thrombolysis Study Group (Cat-SCT)
territory where demographic density is much lower. In 2004, the Health Department of the Autonomous Government of Catalonia created the Stroke Programme as 1 of the branches of the Master Plan for Diseases of the Circulatory System. One of the main objectives of the Stroke Programme was the design of a regionwide model for early evaluation, diagnosis, and treatment of patients with acute stroke based on a pre-existing Stroke Code (SC) system. The main purpose of the SC system is to favor recombinant tissue-type plasminogen activator (rtPA) administration among candidates by facilitating early recognition of stroke and speeding up the transfer of acute patients to referral hospitals (RHs) where immediate assessments can be performed. Our territory-based model disseminated the SC system, operated already by a few hospitals since the late 1990s and beyond, [2] [3] [4] [5] to the whole Catalan territory by drawing a map with 10 healthcare areas within which 13 RHs operate the SC through a local stroke network composed by community hospitals, the emergency medical system, and primary care. This regionwide SC system was fully operative as of May 2006.
The main objectives of this study were to determine safety and effectiveness of intravenous thrombolysis in routine practice after dissemination of the SC system throughout Catalonia and to establish whether newly designated RHs with no previous expertise in thrombolysis performed according to standards. Because all new RHs had been designated according to availability of pre-established technical and professional requirements, we hypothesized that results of intravenous rtPA in routine practice in terms of safety and effectiveness would be comparable to previously published outcomes. Moreover, because we were aware of the potential selection bias linked to unmonitored studies, we assessed safety and effectiveness of thrombolysis in routine practice through a monitored study to estimate the occurrence and magnitude of such bias.
Methods

Study Design and Participating Hospitals
Catalan Stroke Code and Thrombolysis (Cat-SCT) was an observational, prospective study that involved all publicly financed RHs in Catalonia with capacity to assess SC patients and administer alteplase among candidates (nϭ13). RHs were considered experienced (nϭ7) or inexperienced (nϭ6) depending on whether they had begun to administer intravenous rtPA before or after the spread of the SC system, respectively. Thus, RHs that started delivering rtPA in mid-2006, since the dissemination of the SC system by the Stroke Programme, were considered nonexperts. Additionally, 2 community hospitals that operated a telestroke network in connection with 2 experienced RHs were also involved.
All participating hospitals were encouraged to enrol consecutive treatments performed over a 12-month period (October 2007 to October 2008). Inclusion criteria were Ն18-year-old patients with ischemic stroke treated with intravenous rtPA. Treatments administered in combination to any rescue therapy were excluded from this analysis. At each site, designated local investigators were in charge of identifying patients with stroke treated with rtPA, requesting the informed consent, and collecting in-hospital and follow-up data. During the admission, cases were declared to a Web-based registry that satisfied all legal requirements for protection of personal data. Approval was obtained from the Ethics Committee at Institut de Recerca Hospital Universitari Vall d'Hebron (Barcelona, Spain).
Outcome Measures
The primary outcome measures for the Cat-SCT were symptomatic intracerebral hemorrhage (SICH), death, and favorable outcome (defined as a modified Rankin Scale score 0 to 1) after 3 months. SICH was defined according to the Safe Implementation of Thrombolysis in Stroke-MOnitoring STudy (SITS-MOST) protocol 6 as any local or remote parenchymal hemorrhage Type 2 on the 22 to 36 hour post-treatment imaging scan, combined with a neurological deterioration of Ն4 points on the National Institutes of Health Stroke Scale from baseline, or from the lowest National Institutes of Health Stroke Scale value between baseline and 24 hours, or leading to death. Mortality and functional status at 3 months were recorded through face-to-face or telephone follow-up visits performed by local investigators. Whenever a patient was lost to follow-up, survival was retrospectively assessed by study coordinators through official population registries or contact with the patient's family. Secondary outcome measures were functional independence at 3 months (modified Rankin Scale score 0 to 2), death within 7 days and incidence rates of SICH by the European Cooperative Acute Stroke Study definition (any hemorrhage plus a neurological deterioration of Ն4 points on the National Institutes of Health Stroke Scale from baseline or from the lowest National Institutes of Health Stroke Scale value after baseline to 7 days or leading to death). 7 
Quality Control in the Cat-SCT
At the end of the enrollment period, we carried out a comprehensive quality control to assess exhaustiveness or consecutive recruitment and quality of data ( Figure) . In a first step, local stroke databases from all treating hospitals were crosschecked against the central database. Undeclared rtPA treatments retrieved this way were retrospectively included in the Cat-SCT to result in the actual sample (prospectiveϩretrospective inclusions), which was then used to calculate outcomes reported in this article. Second, heads of medical records services among all treating hospitals were requested to produce a local list of all stroke admissions occurred between January 1, 2008, and March 31, 2008, according to predefined International Classification of Diseases, 9th Revision diagnostic codes (431, 432, 433.x1, 434, 436). Discharge and mortality reports from all listed cases were then revised by external monitors in the search of patients treated with intravenous rtPA. International Classification of Diseases, 9th Revision codes corresponding to intravenous thrombolysis (99.10) were discarded as a method for identifying rtPA-treated patients because in a previous stage, we had detected a very low coding rate, similar to what others have described. 8 All cases identified through this process were labeled as declared or undeclared thrombolyses according to their previous inclusion in the central database. Quality of data included at each study site was ensured through external monitoring of patients treated along one fourth of the total recruitment period. Before and during the recruitment period, local collaborators had been warned that a quality control would take place at the end of the study. A registry users' guide and a help line were available along the recruitment period.
Statistical Analyses
We used percentages to describe discrete variables and means (SD) or medians (interquartile range) to describe continuous variables. The proportion and 95% CIs of SICH, mortality, and favorable outcome at 3 months were calculated and compared with those in the SITS-MOST 6 and the pooled results from randomized controlled trials (active group). 9 The effect of hospitals' previous experience on outcomes after intravenous thrombolysis was assessed using multilevel logistic regression analysis. We built 1 model for each outcome variable and added hospitals' previous experience as an explanatory variable adjusting for other baseline variables to take possible differences in the case mix between hospitals into account. Variables for adjustment were selected on the basis of clinical plausibility and a statistical significance for bivariate associations set at a probability value Ͻ0.2. All treatments delivered at community hospitals through telestroke were allocated to the experienced group.
To determine the presence of a potential selection bias, we estimated the rates of primary outcome measures for the potential final sample (ϭactual sampleϩ4*[undeclared treatments detected by the quality control]) and compared it with the rates in the actual sample. All statistical analyses were done using STATA software. The level of significance was set at 0.05.
Results
We studied 488 intravenous thrombolyses included in the actual sample, of which 12 were retrospective inclusions. Three hundred seventy-two of 488 thrombolyses were delivered at experienced RHs (thrombolysis rate: 7.0% of acute ischemic stroke admissions), whereas the remaining 116 treatments were administered at inexperienced RHs (thrombolysis rate: 4.7% of acute ischemic stroke admissions). Numbers of thrombolyses ranged from 10 to 98 across RHs. Seventeen treatments were performed through telestroke. Along the recruitment period, another 34 patients with ischemic stroke received endovascular reperfusion therapies, of which 15 were bridging therapies. Median age of our series was 72 years (IQR: 63, 77), and 279 (57.2%) were males. Compared with patients in the SITS-MOST, those in our study were 4 years older. Accordingly, sex distribution showed a higher percentage of females in our series. Baseline National Institutes of Health Stroke Scale was similar across the Cat-SCT, the SITS-MOST, and the pooled analysis of RCTs, whereas the onset-to-treatment time was longer in the Cat-SCT (Table 1) . Deviations from the SITS-MOST eligibility criteria, particularly of age and time criteria, were detected in 166 (34%) patients, most of who had been treated at experienced RHs ( Table 2) .
As for the primary outcome measures, 16 of 488 (3.3%) patients developed a SICH and 180 of 468 (38.5%) patients achieved a favorable functional outcome. Up to 79 of 468 (16.9%) died within the first 90 days. Overall, outcomes in our series resembled those shown by the pooled analysis of RCTs very much but when compared with the SITS-MOST, patients in the Cat-SCT displayed a significantly higher death rate at 3 months (Table 3) . We also analyzed the influence of RHs' previous experience on outcomes (Table 4 ; http:// stroke.ahajournals.org). Newly designated RHs were at least as safe and effective as experienced RHs. After adjusting for several prognostic factors, we observed non significant trends of higher SICH and mortality rates in experienced centers, whereas chances of achieving a favorable outcome at 3 months were significantly higher for patients treated at inexperienced RHs. After auditing one fourth of the total study period, we detected 3 cases that had not been declared to the Cat-SCT registry, which together with 12 undeclared cases returned by the first step of the quality control, and retrospectively included in the Cat-SCT, set the overall loss at 4.8% (Figure) . The estimated rates of primary outcomes in the potential final sample of 500 patients did not differ significantly from the rates observed in the actual sample (Table 5 ). Regarding the accuracy of outcome measures, death at 7 days had an almost perfect agreement, whereas post-rtPA CT and outcome at 90 days showed moderate agreement. Sources of disagreement were investigated and found to be related to external monitors reporting missing data when local investigators had reported death or a particular score on the modified Rankin Scale, thus suggesting that quality of original data provided by stroke clinicians was good, whereas that of external auditors was improvable.
Discussion
This study shows how an initiative launched by the autonomous health administration, and based on the dissemination of the SC system throughout Catalonia, facilitated the delivery of intravenous thrombolysis in routine practice at the same time as ensuring safety and effectiveness. The results of this study add more evidence to previous knowledge about *Also adjusted for diabetes, antiplatelet treatment and atrial fibrillation. †Also adjusted for previous stroke, pre-morbid mRS, and comorbid conditions (coronary heart disease, congestive heart failure, diabetes, atrial fibrillation, hypertension).
‡Also adjusted for pre-morbid mRS, blood glucose control pre-rtPA, dyslipidemia, and antiplatelet treatment. the reproducibility in clinical practice of outcomes achieved with intravenous rtPA in an experimental setting. However, in our opinion, remarkable contributions of this study are first, it evaluates the impact of health planning on acute stroke care in Catalonia, whereby the SC system was disseminated to cover the whole territory from May 2006. Because the SC dissemination meant designation of new RHs with no previous expertise in thrombolysis, we wanted to assess whether thrombolysis was being delivered safely and effectively. Second, by undertaking a rigorous quality control, we can assure that the results of this study certainly reflect real-world practice, a pivotal feature seldom guaranteed by observational studies. 10 Worldwide thrombolysis rates remain low despite the very many efforts done. 8, 11 Poor recognition of stroke and a delayed alert on the patient's side play a crucial role by stopping patients from benefits of early admission. 12 At the hospital level, certain features of in-hospital organization, particularly clinical leadership, shared goals concerning door-to-needle time and thrombolysis rates and feedback, also contribute to enlarge the numbers of patients with stroke treated with rtPA. 13 At the prehospital level, organization of stroke networks that clearly identify RHs and establishment of referral circuits for patients with acute stroke are of utmost importance, mainly for territories with a public health system and a myriad of differently resourced hospitals. Although local prehospital and in-hospital organization is well known to have an impact on thrombolysis rates of single centers, 2,3,14 from a wider territorial perspective, prehospital organization according to principles of territorial equity is also necessary. 5, 15, 16 This is what we pursued by implementing a sectoring model with 10 SC areas and 13 RHs. 17 These areas work independently and were designed on the basis of 3 main criteria: first, a minimum volume of stroke admissions at each potential RHs that ensured the proper development of the learning curve for intravenous thrombolysis; second, a resident population within the extended catchment areas of designated RHs that would make affordable the estimates of incident SC patients within the area; and third, isochrones of up to 60 minutes from each geographic point within a SC area and its RH. In addition, RHs had to comply with the specific technical and professional requirements for RHs described in our Clinical Practice Guidelines for Stroke 18 and ascertained through local visits by members of the Stroke Programme. Once the RHs and their catchment areas were established, circuits among community hospitals, primary care, and the RHs were defined. The emergency medical system played a role as either the transporter of patients from any of the levels to the RH or as a primary source of SC patients. Neurologists from new RHs who otherwise had no previous experience with intravenous rtPA delivery were asked to undertake short training periods at experienced RHs under the supervision of stroke experts, after which they organized the acute stroke team within their own RHs. In the understanding that responsibilities of health managers follow a logical sequence that goes from planning to evaluation through implementation, we designed and promoted this monitored study to assess the results of our territorial model of acute stroke care.
Our data show that intravenous thrombolysis is just as safe and effective in clinical practice as in major trials. 9, 19 However, when compared with the SITS-MOST, 6 our data show a significant increase in long-term mortality. Possible explanations for this finding are: (1) a difference in median age of 4 years between the SITS-MOST and the Cat-SCT (older patients in the Cat-SCT); (2) a slightly worse previous functional status and slightly higher comorbidity burden among patients included in the Cat-SCT; (3) a 10-minute delay of median onset-totreatment time for patients in the Cat-SCT; and (4) more rigorous quality control in the Cat-SCT. The differences observed in terms of age, comorbidity, and onset-to-treatment time, however, did not evenly apply to the whole cohort and mainly affected patients recruited at experienced hospitals (Table 1) . Routine practice in experienced centers and physicians show a relaxation of rules because well-established label contraindications for rtPA use are questioned on the grounds of experience. 20 In our study, newly designated centers made a much more careful selection of rtPA candidates, whom with very few exceptions fulfilled SITS-MOST criteria ( Table 2 ). This finding is in contrast with existing evidence showing more protocol violations and higher mortality in inexperienced centers. 21, 22 Despite a more accurate patient selection, however, inexperienced RHs did not perform systematically and significantly better across the series of outcomes measured, except for a higher proportion of patients with a modified Rankin Scale score 0 to 1 at 3 months (Table 4) . Moreover, using any protocol violation as a covariate in the multivariate model did not produce any significant change in terms of outcomes compared between experts and nonexperts (data not shown). Thus, protocol violation was not an independent predictor of outcome in our study, suggesting that some other factors play a role (ie, differences in the process of care). However, we believe these findings are not conclusive because the study was not designed to answer this particular question. Although this study cannot confirm nor exclude that differences in outcomes are due to differences in protocol violations, we still believe it necessary to be cautious in selecting patients eligible for rtPA, particularly among experienced hospitals where indication for thrombolysis is frequently made on the basis of radiological mismatch and regardless of the onset-to-treatment time delay. In our study, the proportion of patients treated beyond the 3-hour and 4.5-hour time window were 20.3% (experienced: 25.8%; inexperienced: 2.6%) and 3.9% (experienced: 5.1%; inexperienced: 0%), respectively. In the light of these results as well as existing evidence, 23, 24 thrombolysis beyond the 4.5-hour time window should be cautiously administered in clinical trials only.
This study has some limitations. We analyzed data on 488 patients with stroke treated with intravenous rtPA along 1 year across Catalan hospitals, of which 116 (23.8%) were treated at newly designated hospitals with no previous experience. The trends in favor of safer and more effective treatments at inexperienced RHs are somehow disturbing and need further attention. A longer recruitment period would likely clarify this issue at the same time as offering additional information about changes in rtPA benefits over time. Furthermore, we cannot preclude an effect of unmeasured differences in the case mix of patients treated at experienced and inexperienced RHs on the outcomes. Because we only audited one fourth of the recruitment period, we cannot establish the absence of a selection bias with absolute certainty. However, because the sensitivity analysis showed no distortions, we estimate the magnitude of such bias small. Finally, the methods used for determining the accuracy of data (retrospective review of case records of all stroke admissions treated with rtPA along one fourth of the study period) are improvable. However, a detailed review of the sources of disagreement revealed that those administering thrombolysis provided reliable data. In other words, quality of the original data provided by stroke clinicians was good, whereas that of external auditors was improvable.
In summary, this study shows that health policies that prioritize planning of acute stroke care from a territorial perspective may encourage the use of evidence-based therapies. Accordingly, since SC dissemination across Catalonia, we have observed a gradual increase of intravenous thrombolysis rates, which represented 8.1% of all acute ischemic stroke admissions in 2009. Because thrombolysis carries the potential of harm, we believed it necessary to assess and monitor the outcomes of this particular health planning. Whether this model has external validity and can be applied to other regions or countries with independent health administrations will depend on social and geographic similarities as well as the characteristics of their national health system. 
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